LAMICTAL ODT Drug Patent Profile

When do Lamictal Odt patents expire, and when can generic versions of Lamictal Odt launch?

Lamictal Odt is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LAMICTAL ODT is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lamictal Odt

A generic version of LAMICTAL ODT was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Summary for LAMICTAL ODT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	95
Patent Applications:	4,495
Drug Prices:	Drug price information for LAMICTAL ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAMICTAL ODT
DailyMed Link:	LAMICTAL ODT at DailyMed

See drug prices for LAMICTAL ODT

See drug sales revenues for LAMICTAL ODT

Recent Clinical Trials for LAMICTAL ODT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Desitin Arzneimittel GmbH	PHASE1
BioPharma Services Inc.	PHASE1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all LAMICTAL ODT clinical trials

Pharmacology for LAMICTAL ODT

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for LAMICTAL ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LAMICTAL ODT	Orally Disintegrating Tablets	lamotrigine	25 mg, 50 mg, 100 mg, and 200 mg	022251	1	2009-12-21

US Patents and Regulatory Information for LAMICTAL ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-001	May 8, 2009	AB	RX	Yes	No
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-004	May 8, 2009	AB	RX	Yes	No
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-002	May 8, 2009	AB	RX	Yes	Yes
Glaxosmithkline Llc	LAMICTAL ODT	lamotrigine	TABLET, ORALLY DISINTEGRATING;ORAL	022251-003	May 8, 2009	AB	RX	Yes	No

International Patents for LAMICTAL ODT

See the table below for patents covering LAMICTAL ODT around the world.

Country	Patent Number	Title	Estimated Expiration
Uruguay	31205	COMPOSICIONES DE TABLETAS DE DESINTEGRACION ORAL DE LAMOTRIGINA
Taiwan	I547282
Japan	5346021
China	101801192	Orally disintegrating tablet compositions of lamotrigine
Argentina	068185	COMPOSICIONES DE TABLETAS DE DESINTEGRACION ORAL DE LAMOTRIGINA

LAMICTAL ODT Market Analysis and Financial Projection

Last updated: February 13, 2026

What is Lamictal ODT and its market positioning?

Lamictal ODT (oral disintegrating tablet) is a formulation of lamotrigine, used primarily for treating epilepsy and bipolar disorder. It offers a rapid-dissolving option for patients with swallowing difficulties or adherence issues. Developed by GlaxoSmithKline (GSK) and later marketed by other companies, this formulation caters to a niche within the broader lamotrigine market.

How does the market for Lamictal ODT compare to other formulations?

The overall lamotrigine market surpasses USD 3 billion globally (2022), predominantly driven by tablet and chewable formulations. Lamictal ODT accounts for a fraction of this, estimated at approximately 15-20% of branded lamotrigine sales in developed regions. The quick-dissolving form appeals to pediatric, geriatric, and non-compliant patient segments.

Formulation	Market Share (Global)	Key Benefits	Primary Indications
Standard tablets	65%	Efficacy, cost-effective	Epilepsy, Bipolar
Chewable tablets	15%	Ease of swallowing	Pediatric use
ODT (Lamictal ODT)	15-20%	Rapid onset, convenience, adherence	Pediatric, Geriatric

The slow growth pace stems from market penetration challenges and competition with generic formulations. However, Lamictal ODT maintains a niche, especially where swallowing difficulties are prevalent.

What are the key drivers influencing Lamictal ODT's market growth?

1. Patient Compliance: The ODT form reduces swallowing barriers, improving medication adherence, especially in children and elderly patients.
2. Prescriber Preference: Physicians favor ease of administration for non-compliant or cognitively impaired patients.
3. Market Penetration: Limited by entrenched generic competitors and price sensitivity in emerging markets.
4. Pipeline Alternatives: Development of newer formulations such as sustained-release or implantable devices may curb growth.
5. Regulatory Approvals: US FDA approved Lamictal ODT in 2008; similar approvals in Europe followed, facilitating broader adoption.

How do patent protections and generic entry impact the financial trajectory?

GSK held the original patent on Brand Lamictal until 2014 in the US, allowing for premium pricing. Patent expirations opened the market to generics:

• US Patent Expiry: 2014
• US Generic Market Entry: 2015, leading to significant price erosion.
• Impact on Revenue:
  • GSK's lamotrigine franchise revenue declined by approximately 30% post-generic entry.
  • Lamictal ODT's premium segment faced steep competition, with prices dropping up to 50% within two years.

Despite the decline, branded sales persisted via secondary indications and formulation advantages, but revenue from Lamictal ODT specifically declined more sharply relative to oral tablets.

What are the revenue prospects for Lamictal ODT in the next 5 years?

Forecasts suggest a continued decline in premium-priced formulations due to increasing generic penetration. However, niche use cases in selected markets could sustain "steady" revenues:

• Market Size (2022): Estimated USD 150 million globally.
• Expected CAGR (2023-2028): -5% to -8%, driven by generics and biosimilars.
• Key Markets: US, Japan, and select European countries.

In emerging markets, price sensitivities constrain the growth of branded ODTs. Conversely, in high-income countries, the ODT may sustain a small premium segment due to patient preference.

What are the competitive threats and opportunities ahead?

Threats:

• Entry of biosimilar or generic lamotrigine formulations.
• Development of alternative delivery systems such as patches or long-acting injectables.
• Pricing pressures from payers and healthcare systems.

Opportunities:

• Expansion into new indications or combination therapies.
• Formulation improvements that extend patent life.
• Digital health integrations for adherence monitoring.

How are regulatory policies influencing market dynamics?

The US FDA approved Lamictal ODT in 2008. The European Medicines Agency (EMA) approved it earlier, in 2007. Regulatory pathways remain accessible for new ODT formulations, but reimbursement policies increasingly favor generics, influencing revenue flows.

What is the impact of global health trends on Lamictal ODT?

Rising prevalence of epilepsy and bipolar disorder globally aids sustained demand. The aging population in developed countries increases the relevance of ODT formulations. Market growth remains constrained by generic competition and cost containment policies.

Key Takeaways

• Lamictal ODT's revenue has declined since patent expiration due to generic competition.
• Its niche lies in patient populations with swallowing difficulties.
• Global sales are estimated at USD 150 million, with a negative CAGR projected at around 6% over five years.
• Competitive threats from biosimilars and alternative delivery methods must be monitored.
• Regulatory approvals facilitate market access, but reimbursement policies influence adoption.

FAQs

1. Why has Lamictal ODT's market share decreased?
Patent expiration and the rapid entry of generic lamotrigine products reduce sales of the branded ODT formulation.

2. How does the formulation benefit patients?
It offers rapid disintegration, easing ingestion for patients with swallowing difficulties or adherence issues.

3. Are there any new formulations replacing Lamictal ODT?
Long-acting injectables and transdermal patches are under development but not yet widely available for lamotrigine.

4. Which regions offer growth potential for Lamictal ODT?
Developed countries like the US, Japan, and parts of Europe, where patient compliance drives demand.

5. What strategies could companies use to prolong the product's profitability?
Innovation in formulation to extend patent life, expanding indications, and integrating digital adherence tools.

---

Sources:

[1] MarketWatch, "Lamotrigine Market Analysis," 2022.
[2] IQVIA, "Global Pharmaceutical Market Data," 2022.
[3] FDA database, "Drug Approvals and Patents," 2008-2022.